Literature DB >> 9222127

Purpose and guidelines for toxicokinetic studies within the National Toxicology Program.

J R Buchanan1, L T Burka, R L Melnick.   

Abstract

Toxicokinetic studies undertaken within the National Toxicology Program are intended to aid the design of toxicology and carcinogenicity studies, help interpret the results of toxicology and carcinogenicity studies with respect to the relationship between toxic effects and external exposure, and define the parameters of dose, distribution, metabolism, and elimination that can be used in human risk assessment. Descriptions of two study designs presented here represent the possible extremes in approaches to toxicokinetic studies. The comprehensive approach is geared toward the development of physiology based pharmacokinetic models that relate external exposure to target organ dosimetry and addresses the questions: Is the chemical absorbed? How is the chemical metabolized? Where are the chemical and/or metabolites distributed in the body? What are the elimination rate and route of the chemical? What is the effect of dose on absorption, distribution, metabolism, and elimination? The minimal study design is more limited in scope than the comprehensive design and addresses primarily the issues of absorption, distribution, and elimination of the parent chemical. Study protocols for most chemicals lie somewhere between these two extreme approaches. An increased understanding of the relationships between external exposure, target organ dosimetry, and adverse effects should provide greater confidence in making low-dose extrapolations of human risk. This paper focuses on the collection of data from animal toxicokinetic studies. The construction of comparable models to characterize target organ dosimetry in exposed humans would certainly require the use of human parameter values obtained from human tissue samples and volunteers.

Entities:  

Mesh:

Year:  1997        PMID: 9222127      PMCID: PMC1469880          DOI: 10.1289/ehp.105-1469880

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  2 in total

1.  A vial-equilibration method to evaluate the drug-metabolizing enzyme activity for volatile hydrocarbons.

Authors:  A Sato; T Nakajima
Journal:  Toxicol Appl Pharmacol       Date:  1979-01       Impact factor: 4.219

2.  A partition coefficient determination method for nonvolatile chemicals in biological tissues.

Authors:  G W Jepson; D K Hoover; R K Black; J D McCafferty; D A Mahle; J M Gearhart
Journal:  Fundam Appl Toxicol       Date:  1994-05
  2 in total
  8 in total

1.  DETERMINING DISEASE CAUSALITY FROM EXPERIMENTAL TOXICOLOGY STUDIES.

Authors:  Ronald L Melnick; John R Bucher
Journal:  J Law Policy       Date:  2005

2.  The biological fate of decabromodiphenyl ethane following oral, dermal or intravenous administration.

Authors:  Gabriel A Knudsen; J Michael Sanders; Michael F Hughes; Ethan P Hull; Linda S Birnbaum
Journal:  Xenobiotica       Date:  2016-10-28       Impact factor: 1.908

3.  Playing in the sand.

Authors:  T J Goehl
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

4.  Disposition of the emerging brominated flame retardant, bis(2-ethylhexyl) tetrabromophthalate, in female Sprague Dawley rats: effects of dose, route and repeated administration.

Authors:  Gabriel A Knudsen; J Michael Sanders; Linda S Birnbaum
Journal:  Xenobiotica       Date:  2016-04-21       Impact factor: 1.908

5.  Disposition of the Emerging Brominated Flame Retardant, 2-Ethylhexyl 2,3,4,5-Tetrabromobenzoate, in Female SD Rats and Male B6C3F1 Mice: Effects of Dose, Route, and Repeated Administration.

Authors:  Gabriel A Knudsen; J Michael Sanders; Linda S Birnbaum
Journal:  Toxicol Sci       Date:  2016-09-09       Impact factor: 4.849

Review 6.  Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies.

Authors:  E L Andrade; A F Bento; J Cavalli; S K Oliveira; R C Schwanke; J M Siqueira; C S Freitas; R Marcon; J B Calixto
Journal:  Braz J Med Biol Res       Date:  2016-12-12       Impact factor: 2.590

Review 7.  Should oral gavage be abandoned in toxicity testing of endocrine disruptors?

Authors:  Laura N Vandenberg; Wade V Welshons; Frederick S Vom Saal; Pierre-Louis Toutain; John Peterson Myers
Journal:  Environ Health       Date:  2014-06-25       Impact factor: 5.984

8.  Pharmacokinetic Variability in Pre-Clinical Studies: Sample Study with Abiraterone in Rats and Implications for Short-Term Comparative Pharmacokinetic Study Designs.

Authors:  Jana Královičová; Aleš Bartůněk; Jiří Hofmann; Tomáš Křížek; Petr Kozlík; Jaroslava Roušarová; Pavel Ryšánek; Martin Šíma; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.